cGxP

Consulting

 

 

Biologic Drug Review Transferred to CDER  (September 6th FDA Announcement)

 The responsibility for the review of biologic drug products is being transferred from CBER (Center for Biologics Evaluation and Research) over to CDER (Center for Drug Evaluation and Research).  The FDA announced that the change is being made:

 

 

A detailed article can be found at:  http://www.warningletters.com